RECIST Calculator (RECIST 1.1)

This RECIST Calculator helps assess tumor response to treatment based on the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) by comparing the Sum of Longest Diameters (SLD) of target lesions at baseline and follow-up.

RECIST 1.1 Calculator

What is a RECIST Calculator?

A RECIST Calculator is a tool used in oncology to assess how solid tumors in cancer patients respond to treatment. RECIST stands for “Response Evaluation Criteria in Solid Tumors.” The calculator primarily uses measurements of “target lesions” (selected measurable tumors) at baseline (before or at the start of treatment) and at various follow-up time points.

The core idea is to measure the longest diameter of these target lesions and sum them up to get the Sum of Longest Diameters (SLD). The RECIST Calculator then compares the SLD at follow-up to the baseline SLD (and sometimes the smallest SLD recorded since treatment started, known as nadir) to determine if the tumors have shrunk, grown, or remained stable, or if new lesions have appeared.

Oncologists, radiologists, and researchers in clinical trials use the RECIST Calculator and the underlying RECIST 1.1 criteria to standardize the evaluation of treatment efficacy. This standardization is crucial for comparing results across different studies and patients.

Who Should Use It?

• Oncologists monitoring patient response to therapy.
• Radiologists measuring tumors on imaging scans (like CT or MRI).
• Researchers conducting clinical trials for cancer treatments.
• Medical professionals interpreting trial results.

Common Misconceptions

• It measures all tumors: RECIST focuses on a selection of measurable “target lesions” (up to 5 total, max 2 per organ) and also considers “non-target lesions” and new lesions qualitatively.
• It’s the only measure of response: While widely used, RECIST is one of several criteria (like irRECIST for immunotherapy or Lugano for lymphoma) and is often used alongside other clinical assessments.
• A good RECIST response means cure: A Complete Response (CR) or Partial Response (PR) indicates treatment is working, but it doesn’t always equate to a cure.

RECIST Calculator Formula and Mathematical Explanation

The RECIST Calculator primarily focuses on the change in the Sum of Longest Diameters (SLD) of target lesions.

1. Baseline SLD: Sum of the longest diameters of all target lesions before or at the start of treatment.
   
   Baseline SLD = LD₁ + LD₂ + … + LD_n (where LD_i is the longest diameter of the i-th target lesion, n <= 5)
2. Follow-up SLD: Sum of the longest diameters of the same target lesions at a follow-up assessment.
   
   Follow-up SLD = LD’₁ + LD’₂ + … + LD’_n
3. Percentage Change: The percentage change from baseline is calculated as:
   
   Percentage Change = ((Follow-up SLD – Baseline SLD) / Baseline SLD) * 100%
4. Nadir SLD: The smallest SLD recorded since the treatment started (including baseline). For Progressive Disease (PD), the increase is assessed relative to the nadir SLD. Our basic calculator uses baseline for initial percentage change but nadir is key for PD assessment over time.
5. Response Categories (RECIST 1.1):
   • Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes must have reduced in short axis to <10 mm. Disappearance of all non-target lesions and normalization of tumor markers. No new lesions.
   • Partial Response (PR): At least a 30% decrease in the SLD of target lesions compared to baseline SLD.
   • Progressive Disease (PD): At least a 20% increase in the SLD of target lesions compared to the smallest SLD recorded since treatment started (nadir), AND an absolute increase of at least 5 mm in the SLD. Or, the appearance of one or more new lesions, or unequivocal progression of non-target lesions.
   • Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking nadir SLD as reference.

Variables Table

Variable	Meaning	Unit	Typical Range
LDi	Longest diameter of the i-th target lesion at baseline	mm	≥10 mm (≥15 mm for lymph nodes short axis)
LD’i	Longest diameter of the i-th target lesion at follow-up	mm	0 to > baseline
Baseline SLD	Sum of LDi at baseline	mm	Varies
Follow-up SLD	Sum of LD’i at follow-up	mm	Varies
Nadir SLD	Smallest SLD recorded since treatment began	mm	Varies

Table explaining the variables used in the RECIST Calculator.

Practical Examples (Real-World Use Cases)

Example 1: Partial Response

A patient with lung cancer has two target lesions measured at baseline:

• Lesion 1: 30 mm
• Lesion 2: 20 mm

Baseline SLD = 30 + 20 = 50 mm.

After 3 months of treatment, the lesions are measured again:

• Lesion 1: 15 mm
• Lesion 2: 15 mm

Follow-up SLD = 15 + 15 = 30 mm.

Percentage Change = ((30 – 50) / 50) * 100 = -40%.

Since the decrease is more than 30%, this is classified as a Partial Response (PR), assuming no new lesions and non-target lesions are not progressing unequivocally.

Example 2: Progressive Disease

A patient with colon cancer has one target lesion:

• Baseline: 40 mm (Baseline SLD = 40 mm, Nadir SLD = 40mm initially)
• Follow-up 1 (2 months): 30 mm (New Nadir SLD = 30mm) – SD
• Follow-up 2 (4 months): 38 mm

Comparing Follow-up 2 to Nadir (30 mm):

Percentage Change from Nadir = ((38 – 30) / 30) * 100 = 26.67%

Absolute increase from Nadir = 38 – 30 = 8 mm.

The percentage increase (26.67%) is greater than 20%, AND the absolute increase (8 mm) is greater than 5 mm. Therefore, this is classified as Progressive Disease (PD) at Follow-up 2.

How to Use This RECIST Calculator

1. Select Number of Lesions: Choose the number of target lesions (1 to 5) you are tracking using the dropdown.
2. Enter Baseline Diameters: For each target lesion, enter its longest diameter in millimeters (mm) measured at baseline.
3. Enter Follow-up Diameters: For the same lesions, enter their longest diameters in millimeters (mm) measured at the follow-up scan. If a lesion disappeared, enter 0.
4. Calculate Response: Click the “Calculate Response” button.
5. Read Results: The calculator will display:
   • Baseline SLD
   • Follow-up SLD
   • Percentage Change in SLD from baseline
   • The RECIST response category (CR, PR, SD, or PD based on change from baseline and absolute increase for PD). Note: For accurate PD assessment over multiple cycles, comparison to nadir is essential, which this calculator simplifies by comparing to baseline but highlights the PD criteria.
6. Interpret: Use the response category and percentage change to understand the tumor’s reaction to the treatment, in conjunction with non-target lesion assessment and the appearance of new lesions (which are not directly input into this simplified calculator but are part of full RECIST). See our article on non-target lesions.

Key Factors That Affect RECIST Results

• Measurement Variability: Inter-observer and intra-observer variability in measuring lesions can impact SLD and consequently the response category. Using consistent measurement techniques is vital.
• Image Quality and Modality: The quality of CT or MRI scans and the imaging modality used can affect lesion delineation and measurement.
• Selection of Target Lesions: The choice of target lesions at baseline is crucial. They must be measurable (typically ≥10 mm, or ≥15 mm short axis for lymph nodes) and reproducible.
• Appearance of New Lesions: The appearance of any new lesion, regardless of the change in target lesions, generally signifies Progressive Disease (PD). Our RECIST calculator focuses on target lesions but new lesions are critical.
• Behavior of Non-Target Lesions: Unequivocal progression of non-target lesions can also indicate PD, even if target lesions are stable or responding. Read more about non-target lesions.
• Nadir SLD: For PD assessment, the comparison is made against the smallest SLD recorded since treatment start (nadir), not just baseline after the first follow-up.
• Time Point of Assessment: Assessments are typically done at predefined intervals. The timing can influence the observed response. More about this in clinical trials explained.
• Tumor Cavitation/Necrosis: Sometimes tumors may increase in size due to necrosis or cavitation after treatment, which might not represent true progression. Careful radiological interpretation is needed.

Frequently Asked Questions (FAQ)

Q1: What does RECIST 1.1 stand for?
A1: RECIST 1.1 refers to the Response Evaluation Criteria in Solid Tumors, version 1.1, which is the updated set of rules published in 2009 for assessing tumor response in clinical trials and practice.

Q2: What is the minimum size for a measurable target lesion in RECIST 1.1?
A2: Generally, lesions must have a longest diameter of at least 10 mm to be considered measurable target lesions. For lymph nodes, the short axis must be at least 15 mm.

Q3: How many target lesions are selected?
A3: A maximum of 5 target lesions in total, and a maximum of 2 target lesions per organ, are selected at baseline and followed throughout the study.

Q4: What if a target lesion disappears at follow-up?
A4: If a target lesion is no longer measurable or has disappeared, its longest diameter at follow-up is recorded as 0 mm for the SLD calculation (or 5mm if it becomes too small to measure but still visible and not 0, though often it’s 0 if gone). Complete Response requires all target lesions to disappear.

Q5: What is the difference between target and non-target lesions?
A5: Target lesions are selected, measurable lesions followed with precise measurements. Non-target lesions are other lesions that are present but not measured precisely; they are assessed qualitatively for overall response or progression. Learn about non-target lesions.

Q6: How is Progressive Disease (PD) defined more precisely?
A6: PD is defined as at least a 20% increase in the SLD compared to the smallest SLD recorded since treatment start (nadir), with an absolute increase of at least 5 mm. It can also be declared based on the appearance of new lesions or unequivocal progression of non-target lesions. Understanding nadir in RECIST is key.

Q7: Can this RECIST Calculator be used for all types of cancer?
A7: RECIST is primarily designed for solid tumors. Hematological malignancies (like leukemia or lymphoma) and some other cancers have different response criteria (e.g., Lugano criteria for lymphoma).

Q8: What if a patient develops new lesions?
A8: The appearance of one or more new lesions is generally considered Progressive Disease (PD), even if the target lesions are shrinking. Our basic RECIST calculator doesn’t take new lesions as input, but it’s a critical part of the full criteria. Explore common cancer treatments and their monitoring.